PE20110150A1 - Amidofenoxiindazoles como inhibidores de c-met - Google Patents

Amidofenoxiindazoles como inhibidores de c-met

Info

Publication number
PE20110150A1
PE20110150A1 PE2011000061A PE2011000061A PE20110150A1 PE 20110150 A1 PE20110150 A1 PE 20110150A1 PE 2011000061 A PE2011000061 A PE 2011000061A PE 2011000061 A PE2011000061 A PE 2011000061A PE 20110150 A1 PE20110150 A1 PE 20110150A1
Authority
PE
Peru
Prior art keywords
methyl
ilmethyl
amidophenoxyndazoles
met inhibitors
pyrazole
Prior art date
Application number
PE2011000061A
Other languages
English (en)
Spanish (es)
Inventor
Tiechao Li
Mark Andrew Pobanz
Chuan Shih
Zhipei Wu
Wei Jennifer Yang
Boyu Zhong
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20110150A1 publication Critical patent/PE20110150A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PE2011000061A 2008-07-24 2009-07-15 Amidofenoxiindazoles como inhibidores de c-met PE20110150A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8329408P 2008-07-24 2008-07-24
US8508208P 2008-07-31 2008-07-31
US10865908P 2008-10-27 2008-10-27

Publications (1)

Publication Number Publication Date
PE20110150A1 true PE20110150A1 (es) 2011-03-07

Family

ID=41010247

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011000061A PE20110150A1 (es) 2008-07-24 2009-07-15 Amidofenoxiindazoles como inhibidores de c-met

Country Status (35)

Country Link
US (2) US8030302B2 (enExample)
EP (1) EP2310382B1 (enExample)
JP (1) JP5414794B2 (enExample)
KR (1) KR101334456B1 (enExample)
CN (1) CN102105462B (enExample)
AR (1) AR074632A1 (enExample)
AT (1) ATE546444T1 (enExample)
AU (1) AU2009274256B2 (enExample)
BR (1) BRPI0916286B8 (enExample)
CA (1) CA2731773C (enExample)
CL (1) CL2011000134A1 (enExample)
CO (1) CO6351737A2 (enExample)
CR (1) CR20110046A (enExample)
CY (1) CY1112595T1 (enExample)
DK (1) DK2310382T3 (enExample)
DO (1) DOP2011000009A (enExample)
EA (1) EA018385B1 (enExample)
EC (1) ECSP11010778A (enExample)
ES (1) ES2379587T3 (enExample)
HR (1) HRP20120202T1 (enExample)
IL (1) IL210490A (enExample)
JO (1) JO2788B1 (enExample)
MA (1) MA32594B1 (enExample)
MX (1) MX2011000925A (enExample)
MY (1) MY163852A (enExample)
NZ (1) NZ590013A (enExample)
PE (1) PE20110150A1 (enExample)
PL (1) PL2310382T3 (enExample)
PT (1) PT2310382E (enExample)
RS (1) RS52261B (enExample)
SI (1) SI2310382T1 (enExample)
SV (1) SV2011003816A (enExample)
TW (1) TWI365185B (enExample)
WO (1) WO2010011538A1 (enExample)
ZA (1) ZA201100219B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009303602B2 (en) 2008-10-14 2012-06-14 Sunshine Lake Pharma Co., Ltd. Compounds and methods of use
EP2408300B1 (en) 2009-03-21 2016-05-11 Sunshine Lake Pharma Co., Ltd. Amino ester derivatives, salts thereof and methods of use
MX352844B (es) 2011-02-28 2017-12-11 Calitor Sciences Llc Compuestos de quinolina sustituidos y metodos de uso.
JP5970003B2 (ja) * 2011-03-04 2016-08-17 ローカス ファーマシューティカルズ インコーポレイテッド アミノピラジン化合物
KR20130118612A (ko) * 2012-04-20 2013-10-30 (주)네오믹스 신규한 아미노피리딘 유도체 및 이의 용도
CA2869316C (en) * 2012-05-09 2016-12-20 Eli Lilly And Company Anti-c-met antibodies
JP6433922B2 (ja) * 2013-02-27 2018-12-05 アレイ バイオファーマ、インコーポレイテッド インダゾール誘導体の調製に使用するための中間体およびその調製方法
CN104140393B (zh) * 2013-12-10 2016-09-21 郑州泰基鸿诺医药股份有限公司 一种芳环/芳杂环叔丁醇酯类化合物的制备方法
WO2015164161A1 (en) 2014-04-22 2015-10-29 Calitor Sciences, Llc Bicylcic pyrazolone compounds and methods of use
TW201716085A (zh) * 2015-08-12 2017-05-16 應克隆公司 癌症之組合療法
EP3442573A1 (en) * 2016-04-15 2019-02-20 Eli Lilly and Company Combination of ramucirumab and merestinib for use in treatment of colorectal cancer
JP7599819B2 (ja) 2016-06-02 2024-12-16 イムノコア リミテッド gp100特異的TCR-抗CD3 scFv融合タンパク質の投薬レジメン
EP3490676A1 (en) * 2016-07-29 2019-06-05 Eli Lilly and Company Combination therapy with merestinib and anti-pd-l1 or anti-pd-1 inhibitors for use in the treatment of cancer
CN108069938A (zh) * 2016-11-15 2018-05-25 中国药科大学 2,4-二取代吡啶类化合物及其制备方法和应用
JP2019536771A (ja) * 2016-11-16 2019-12-19 イーライ リリー アンド カンパニー エクソン14スキッピング変異またはエクソン14スキッピング表現型を有する癌の治療
US20210283249A1 (en) 2016-11-16 2021-09-16 Eli Lilly And Company Combination therapy for cancer with exon 14 skipping mutation(s) or exon 14 skipping phenotype
CN107382968A (zh) * 2017-07-06 2017-11-24 北京万全德众医药生物技术有限公司 一种吲哚类c‑Met抑制剂的制备方法
CN107311983A (zh) * 2017-07-06 2017-11-03 北京万全德众医药生物技术有限公司 吲哚类小分子c‑met抑制剂
US10180422B1 (en) 2017-08-22 2019-01-15 Scripps Health Methods of treating a neuroendocrine tumor
EP3480201A1 (en) 2017-11-06 2019-05-08 Oncostellae, S.L. New analogs as androgen receptor and glucocorticoid receptor modulators
CN111372925B (zh) 2017-11-24 2022-09-02 南京明德新药研发有限公司 作为c-MET/AXL抑制剂的尿嘧啶类化合物
CN110041316B (zh) * 2018-01-17 2022-04-19 药捷安康(南京)科技股份有限公司 Tam家族激酶/和csf1r激酶抑制剂及其用途
EP3762392B1 (en) 2018-03-08 2024-05-15 Wellmarker Bio Co., Ltd. Thienopyridine derivatives and pharmaceutical composition comprising same
PT3842425T (pt) * 2018-08-24 2024-07-02 Transthera Sciences Nanjing Inc Novo inibidor derivado de quinolina
CN112739691B (zh) * 2018-09-03 2023-05-23 泰励生物科技(上海)有限公司 用作抗癌药的trk抑制剂
JP2022554042A (ja) 2019-09-06 2022-12-28 ウェルマーカー・バイオ・カンパニー・リミテッド バイオマーカー型治療用組成物
US20240293386A1 (en) * 2021-06-22 2024-09-05 Lg Chem, Ltd. Novel compound as protein kinase inhibitor
WO2023110936A1 (en) 2021-12-14 2023-06-22 Netherlands Translational Research Center Holding B.V Reversible macrocyclic kinase inhibitors

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO155316C (no) * 1982-04-23 1987-03-11 Sintef Fremgangsmaate for fremstilling av magnetiske polymerpartikler.
US5484681A (en) * 1994-10-31 1996-01-16 Xerox Corporation Conductive composite particles and processes for the preparation thereof
IL114149A0 (en) * 1995-06-14 1995-10-31 Yeda Res & Dev Modified avidin and streptavidin molecules and use thereof
US5747577A (en) * 1995-12-27 1998-05-05 Xerox Corporation Conductive particles containing carbon black and processes for the preparation thereof
DE10046029A1 (de) 2000-09-18 2002-03-28 Bayer Ag Indazole
EP1400808B1 (en) * 2001-05-18 2006-06-28 Srl, Inc. Immunoassay method
US6956084B2 (en) * 2001-10-04 2005-10-18 Bridgestone Corporation Nano-particle preparation and applications
JP2004067703A (ja) * 2002-04-24 2004-03-04 Japan Science & Technology Corp 架橋ポリマー、微粒子および製造方法
US7192780B2 (en) * 2002-10-23 2007-03-20 Evident Technologies Fluorescent lifetime biological detection and imaging using water-stable semiconductor nanocrystals
ES2273047T3 (es) 2002-10-28 2007-05-01 Bayer Healthcare Ag Fenilaminopirimidinas sustituidas con heteroariloxi como inhibidores de rho-cinasa.
CN102746529B (zh) * 2003-07-17 2015-11-18 生命科技公司 包覆的磁性颗粒的制备方法
US7163998B2 (en) * 2003-09-09 2007-01-16 Eastman Kodak Company Stabilized polymer beads and method of preparation
US20050288290A1 (en) * 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
US7439246B2 (en) * 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
RS55630B1 (sr) 2005-12-21 2017-06-30 Janssen Pharmaceutica Nv Triazolopiridazini kao modulatori tirozin kinaze
US7723330B2 (en) * 2006-03-07 2010-05-25 Array Biopharma Inc. Heterobicyclic pyrazole compounds and methods of use
EP2038320B1 (en) * 2006-06-29 2014-03-12 Life Technologies AS Particles containing multi- block polymers
PE20121506A1 (es) 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
BRPI0717320A2 (pt) 2006-10-23 2013-10-22 Sgx Pharmaceuticals Inc Triazóis bicíclicos como moduladores de proteína cinase
WO2009003084A1 (en) 2007-06-27 2008-12-31 Arkema Inc. Process for the manufacture of hydrofluoroolefins

Also Published As

Publication number Publication date
CN102105462B (zh) 2014-07-23
US20100022529A1 (en) 2010-01-28
IL210490A0 (en) 2011-03-31
IL210490A (en) 2013-06-27
JP2011529054A (ja) 2011-12-01
HRP20120202T1 (hr) 2012-03-31
CY1112595T1 (el) 2016-02-10
DK2310382T3 (da) 2012-03-26
PT2310382E (pt) 2012-04-11
NZ590013A (en) 2012-06-29
RS52261B (sr) 2012-10-31
SI2310382T1 (sl) 2012-04-30
ATE546444T1 (de) 2012-03-15
AU2009274256B2 (en) 2013-07-11
EA018385B1 (ru) 2013-07-30
SV2011003816A (es) 2011-03-17
CL2011000134A1 (es) 2011-07-08
KR20110022691A (ko) 2011-03-07
WO2010011538A1 (en) 2010-01-28
JP5414794B2 (ja) 2014-02-12
ZA201100219B (en) 2012-06-27
CO6351737A2 (es) 2011-12-20
HK1155172A1 (en) 2012-05-11
US8030302B2 (en) 2011-10-04
USRE43878E1 (en) 2012-12-25
CA2731773C (en) 2013-03-12
CR20110046A (es) 2011-04-27
AU2009274256A1 (en) 2010-01-28
MY163852A (en) 2017-10-31
MX2011000925A (es) 2011-03-21
KR101334456B1 (ko) 2013-11-29
PL2310382T3 (pl) 2012-07-31
ECSP11010778A (es) 2011-02-28
DOP2011000009A (es) 2011-03-31
TWI365185B (en) 2012-06-01
BRPI0916286B8 (pt) 2021-05-25
CN102105462A (zh) 2011-06-22
EP2310382B1 (en) 2012-02-22
AR074632A1 (es) 2011-02-02
TW201006817A (en) 2010-02-16
ES2379587T3 (es) 2012-04-27
EA201170252A1 (ru) 2011-06-30
MA32594B1 (fr) 2011-09-01
BRPI0916286B1 (pt) 2019-10-08
CA2731773A1 (en) 2010-01-28
JO2788B1 (en) 2014-03-15
EP2310382A1 (en) 2011-04-20

Similar Documents

Publication Publication Date Title
PE20130375A1 (es) Compuestos de triazolopiridinas y triazolopirazinas inhibidores de c-met y composiciones de los mismos
PE20141678A1 (es) Indazol-3-carboxamidas y su uso como inhibidores de la ruta de senalizacion de wnt/b-catenina
PE20081262A1 (es) Derivados de fenilo como moduladores de cinasas y composiciones
CR20110264A (es) Pirazolilaminopiridinas como inhibidores de fak
PE20150041A1 (es) Derivados de aminoacidos funcionalizados en la terminal n capaces de formar microesferas encapsuladoras de farmaco
ECSP12012293A (es) Ciertas amino-pirimidinas, composicioines de las mismas y métodos para el uso de los mismos
PE20090601A1 (es) Derivados de piridin-il-oxi-piridinas como inhibidores de alk5
ECSP11011151A (es) Compuestos purina
PE20140171A1 (es) Pirazoles fungicidas y sus mezclas
PE20090772A1 (es) Derivados de bencimidazol
MX343264B (es) Ciertas amino-piridazinas, composiciones de las mismas y metodos de uso de los mismos.
CO6321276A2 (es) Derivados de tiazol usados como inhibidores de pi3- cinasa
PE20140192A1 (es) Derivados de bencimidazol como inhibidores de cinasa pi3
EA201001682A1 (ru) Производные фенил- и бензодиоксинилзамещенных индазолов
PE20141050A1 (es) Inhibidores de quinasa relacionados con pirrolo (2,3-d) pirimidina tropomiosina
AR077977A1 (es) Compuestos y composiciones como inhibidores de cinasa de proteina
EA201100037A1 (ru) Органические соединения
SV2011003831A (es) Compuestos organicos
PE20120495A1 (es) 3-ciclopentilamino-2,2-difluor-propanoato de etilo como intermediario en la preparacion de pirimidodiazepinas
PE20140868A1 (es) Antagonistas trpm8 y su uso en tratamientos
PE20110665A1 (es) Compuestos derivados de n-cichohexil-3-(fenilamino)-isonicotinamida como inhibidores de mek
EA201101621A1 (ru) Производные бензоксазолона в качестве ингибиторов альдостеронсинтазы
UY31750A (es) Compuestos y composiciones como inhibidores de quinasa
PE20151748A1 (es) Inhibidores de bace1
PA8855001A1 (es) Monocarbamas

Legal Events

Date Code Title Description
FG Grant, registration